Diagnosing brain diseases such as Parkinson’s disease and dementia can be very difficult, especially in the early stages.
Many of these conditions share similar symptoms, including memory loss, movement problems, and changes in thinking. Because of this overlap, doctors sometimes struggle to make the correct diagnosis, which can delay proper treatment or even lead to the wrong care.
Now, an international team of scientists has made an important breakthrough that could change how these diseases are diagnosed.
In a study published in the journal Nature Medicine, researchers have identified a new biological marker in cerebrospinal fluid that may help doctors distinguish between Parkinson’s disease, Lewy body dementia, and other conditions such as Alzheimer’s disease.
Cerebrospinal fluid, often called CSF, is a clear liquid that surrounds and protects the brain and spinal cord. Because it is in close contact with the brain, it can carry important information about what is happening inside the nervous system. For this reason, scientists often study this fluid to look for signs of disease.
The research team was led by scientists from the University Medical Center in Amsterdam, including Dr. Katharina Bolsewig and Professor Charlotte Teunissen, with contributions from Professor Sebastiaan Engelborghs in Belgium. Their work focused on a protein called DOPA decarboxylase.
This protein plays a key role in producing dopamine, a chemical in the brain that is essential for movement, mood, and many other functions. Parkinson’s disease is known to involve a loss of dopamine-producing cells, which leads to the movement symptoms seen in patients. Lewy body dementia also involves problems with dopamine and other brain systems.
The researchers discovered that levels of DOPA decarboxylase in cerebrospinal fluid were much higher in people with Parkinson’s disease or Lewy body dementia compared to healthy individuals.
Importantly, these levels were also clearly different from those found in patients with Alzheimer’s disease. This means the test could help doctors tell these conditions apart more accurately.
In the study, the team developed two highly sensitive laboratory methods to measure this protein in cerebrospinal fluid. They found that the levels in affected patients could be up to two and a half times higher than in people without these diseases. In addition, higher levels of the protein were linked to more severe changes in the brain, suggesting that the marker reflects the underlying disease process.
This discovery is especially important because Lewy body dementia is often misdiagnosed. Its symptoms can overlap with both Alzheimer’s disease and Parkinson’s disease, making it difficult to identify correctly. When patients are misdiagnosed, they may receive treatments that are not effective or, in some cases, may even worsen their condition.
Having a reliable and objective test could help doctors make earlier and more accurate decisions about diagnosis and treatment. This could improve patient care and reduce uncertainty for both patients and their families.
Although the results are very promising, the researchers note that more work is needed before this test becomes widely available in everyday clinical practice. The testing methods need to be standardized so that results are consistent across different laboratories and healthcare systems.
This study highlights the value of international collaboration in medical research. By bringing together experts from different countries and fields, the team was able to make a discovery that could have a real impact on how brain diseases are diagnosed.
In conclusion, the identification of DOPA decarboxylase as a biomarker in cerebrospinal fluid represents a major step forward in the field of neurology. The study provides strong evidence that this protein can help distinguish between different neurodegenerative diseases, which has long been a challenge in medicine.
However, further research is needed to confirm these findings in larger patient groups and to ensure that the test can be safely and effectively used in clinical settings. If successful, this approach could lead to earlier diagnosis, better treatment choices, and improved outcomes for people living with Parkinson’s disease and dementia.
If you care about Parkinson’s disease, please read studies that Vitamin B may slow down cognitive decline, and Mediterranean diet could help lower risk of Parkinson’s.
For more information about brain health, please see recent studies that blueberry supplements may prevent cognitive decline, and results showing Plant-based diets could protect cognitive health from air pollution.
Copyright © 2026 Knowridge Science Report. All rights reserved.
